Monroe, I’m sure you and many others on this board see Leronlimab for what it is. A term I like to coin is an: IDM (Industry Disrupting Molecule). It’s broad application and zero side effects profile makes this drug best in class for decades to come. This company will not look the same 1 year from today, if not 6 months. NP is very ambitious, to say the least, About having ten clinical trials by the end of this year... but if this molecule works the way we think and have seen to, ambitious will only be in relation to how many trials we can start, and not necessarily the indications they pursue. Best of luck all! See ya in December!!!!!
Market Data 
Markets 
AI
